Pharmacological Strategies for COVID-19 - A Review of the Most Promising Repurposed Antiviral Drugs

(E-pub Ahead of Print)

Author(s): Deepti Chopra, Jaspreet K Boparai, Bharti Bhandari*, Anurag Srivastava, Rakesh Gupta

Journal Name: Infectious Disorders - Drug Targets
Formerly Current Drug Targets - Infectious Disorders

Article ID: e160921189260
Become EABM
Become Reviewer
Call for Editor


A novel coronavirus, SARS-CoV-2 (2019-nCoV) emerged in December 2019 as an immediate global challenge. Comprehensive efforts at present time are focused simultaneously on containing spread of this virus and extenuating the ill effects. There is an immediate need for drugs that can help before a vaccine can be developed. Researchers are endeavoring to find antiviral therapies specific to the virus. As the condition is an emerging, rapidly evolving situation and development of new drugs is a long process, and is unfeasible to face the immediate global challenge. Strategy to reposition the previously used drugs can prove to be effective to combat this difficult to treat situation. Several drugs such as Hydroxychloroquine, Umifenovir, Remdesivir, Lopinavir/Ritonavir, interferon, Darunavir, Favipiravir, Nitazoxanide etc. are currently undergoing clinical studies to test the safety and efficacy of the drug against this pandemic. The present review gives a snapshot look of the current clinical experience with repurposed antiviral drugs.

Keywords: COVID-19, 2019-nCoV, SARS-CoV-2, novel coronavirus, repurposed drugs, antiviral therapies

Rights & PermissionsPrintExport Cite as

Article Details

Article ID: e160921189260
Published on: 18 December, 2020
(E-pub Ahead of Print)
DOI: 10.2174/1871526520666201218151841
Price: $95

Article Metrics

PDF: 246